Melissa A. Crosby
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Melissa A. Crosby has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
Mark T. Villa
5 shared publications- David W. Chang
The University of Texas MD Anderson Cancer Center
4 shared publications Donald P. Baumann
4 shared publications- Alexander T. Nguyen
The University of Texas MD Anderson Cancer Center, Houston, TX, USA
2 shared publications - Edward I. Chang
From the Department of Plastic Surgery, University of Texas MD Anderson Cancer Center
2 shared publications Elizabeth A. Mittendorf
2 shared publications
Latest Publications
- Open Access
- 20 September 2016
- Published by Springer Nature in Breast Cancer Research
- Vol. 18 (1) , 1-13
Outcomes of contralateral prophylactic mastectomy in relation to familial history: a decision analysis (BRCR-D-16-00033)
Family history of breast cancer is associated with an increased risk of contralateral breast cancer (CBC) even in the absence of mutations in the breast cancer susceptibility genes BRCA1/2. We compared quality-adjusted survival after contralateral prophylactic mastectomy (CPM) with surveillance only (no CPM) among women with breast cancer incorporating the degree of family history. We created a microsimulation model for women with first-degree, second-degree, and no family history treated for a stage I, II, or III estrogen receptor (ER)-positive or ER-negative breast cancer at the ages of 40, 50, 60, and 70. The model incorporated a 10-year posttreatment period for risk of developing CBC and/or dying of the primary cancer or CBC. For each patient profile, we used 100,000 microsimulation trials to estimate quality-adjusted life expectancy for the clinical strategies CPM and no CPM. CPM showed minimal improvement on quality-adjusted life expectancy among women age 50–60 with no or a unilateral first-degree or second-degree family history (decreasing from 0.31 to –0.06 quality-adjusted life-years (QALYs)) and was unfavorable for most subgroups of women age 70 with stage III breast cancer regardless of degree of family history (range –0.08 to –0.02 QALYs). Sensitivity analysis showed that the highest predicted benefit of CPM assuming 95 % risk reduction in CBC was 0.57 QALYs for a 40-year-old woman with stage I breast cancer who had a first-degree relative with bilateral breast cancer. Women age 40 with stage I breast cancer and a first-degree relative with bilateral breast cancer have a QALY benefit from CPM similar to that reported for BRCA1/2 mutation carriers. For most subgroups of women, CPM has a minimal to no effect on quality-adjusted life expectancy, irrespective of family history of breast cancer.
- 20 September 2016
- Published by Springer Nature in Breast Cancer Research
- Vol. 18 (1) , 1-13
Open AccessOutcomes of contralateral prophylactic mastectomy in relation to familial history: a decision analysis (BRCR-D-16-00033)
Family history of breast cancer is associated with an increased risk of contralateral breast cancer (CBC) even in the absence of mutations in the breast cancer susceptibility genes BRCA1/2. We compared quality-adjusted survival after contralateral prophylactic mastectomy (CPM) with surveillance only (no CPM) among women with breast cancer incorporating the degree of family history. We created a microsimulation model for women with first-degree, second-degree, and no family history treated for a stage I, II, or III estrogen receptor (ER)-positive or ER-negative breast cancer at the ages of 40, 50, 60, and 70. The model incorporated a 10-year posttreatment period for risk of developing CBC and/or dying of the primary cancer or CBC. For each patient profile, we used 100,000 microsimulation trials to estimate quality-adjusted life expectancy for the clinical strategies CPM and no CPM. CPM showed minimal improvement on quality-adjusted life expectancy among women age 50–60 with no or a unilateral first-degree or second-degree family history (decreasing from 0.31 to –0.06 quality-adjusted life-years (QALYs)) and was unfavorable for most subgroups of women age 70 with stage III breast cancer regardless of degree of family history (range –0.08 to –0.02 QALYs). Sensitivity analysis showed that the highest predicted benefit of CPM assuming 95 % risk reduction in CBC was 0.57 QALYs for a 40-year-old woman with stage I breast cancer who had a first-degree relative with bilateral breast cancer. Women age 40 with stage I breast cancer and a first-degree relative with bilateral breast cancer have a QALY benefit from CPM similar to that reported for BRCA1/2 mutation carriers. For most subgroups of women, CPM has a minimal to no effect on quality-adjusted life expectancy, irrespective of family history of breast cancer.
- 1 October 2014
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 219 (4) , e123
Free flap for limb salvage following oncologic resection: 12-year experience
- 1 October 2014
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 219 (4) , e123
Free flap for limb salvage following oncologic resection: 12-year experience
- 1 October 2014
- Published by Wolters Kluwer Health in Plastic and Reconstructive Surgery
- Vol. 134, 40-41
Free Flap for Limb Salvage Following Oncologic Resection
- 1 October 2014
- Published by Wolters Kluwer Health in Plastic and Reconstructive Surgery
- Vol. 134, 40-41
Free Flap for Limb Salvage Following Oncologic Resection
- 1 September 2013
- Published by Wolters Kluwer Health in Plastic and Reconstructive Surgery
- Vol. 132 (3) , 723-724
Elisabeth K. Beahm, M.D., 1959 to 2013
- 1 September 2013
- Published by Wolters Kluwer Health in Plastic and Reconstructive Surgery
- Vol. 132 (3) , 723-724
Elisabeth K. Beahm, M.D., 1959 to 2013
- 1 July 2013
- Published by Wolters Kluwer Health in Plastic and Reconstructive Surgery
- Vol. 132 (1) , 174e-175e
Reply
- 1 July 2013
- Published by Wolters Kluwer Health in Plastic and Reconstructive Surgery
- Vol. 132 (1) , 174e-175e
Reply
- 4 February 2013
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 39 (6) , 673-681
Developing a theoretical framework to illustrate associations among patient satisfaction, body image and quality of life for women undergoing breast reconstruction
- 4 February 2013
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 39 (6) , 673-681
Developing a theoretical framework to illustrate associations among patient satisfaction, body image and quality of life for women undergoing breast reconstruction
- 1 November 2012
- Published by Wolters Kluwer Health in Plastic and Reconstructive Surgery
- Vol. 130 (5) , 750e-751e
Reply
- 1 November 2012
- Published by Wolters Kluwer Health in Plastic and Reconstructive Surgery
- Vol. 130 (5) , 750e-751e
Reply
- 1 May 2012
- Published by Wolters Kluwer Health in Plastic and Reconstructive Surgery
- Vol. 129 (5) , 789e-795e
Immediate Breast Reconstruction and Lymphedema Incidence
As breast cancer survivorship increases, more women are being affected by treatment sequelae, including lymphedema. The purpose of this study was to evaluate lymphedema incidence among immediate breast reconstruction patients and determine what factors are associated with lymphedema, including reconstruction method. The authors reviewed the outcomes of all consecutive patients who underwent immediate postmastectomy breast reconstruction at their institution between 2001 and 2006. Patient, treatment, and outcome characteristics were compared among reconstruction types: expander and implant, latissimus dorsi myocutaneous flap and implant, and autologous flap alone. Regression models were used to determine whether patient and treatment characteristics were associated with lymphedema development. This study included 1117 patients (1499 breasts), with a mean follow-up of 56 months. Axillary interventions (p < 0.001), high numbers of positive lymph nodes (p = 0.004), postoperative radiation therapy (p = 0.007), and body mass index of 25 kg/m or greater (p = 0.010) were strong predictors of increased lymphedema incidence. After excluding prophylactic mastectomy and reconstruction group changes, the authors found that the mean lymphedema incidence was 4.0 percent (of 1013 breasts). Reconstruction type had no significant effect on incidence of or time to lymphedema, and no interaction was found between axillary intervention and reconstruction type (p = 0.799). The incidence of lymphedema after immediate reconstruction was associated with high body mass index, axillary interventions, and high numbers of positive lymph nodes. The reconstructive method did not appear to affect lymphedema incidence or timing. Risk, III.
- 1 May 2012
- Published by Wolters Kluwer Health in Plastic and Reconstructive Surgery
- Vol. 129 (5) , 789e-795e
Immediate Breast Reconstruction and Lymphedema Incidence
As breast cancer survivorship increases, more women are being affected by treatment sequelae, including lymphedema. The purpose of this study was to evaluate lymphedema incidence among immediate breast reconstruction patients and determine what factors are associated with lymphedema, including reconstruction method. The authors reviewed the outcomes of all consecutive patients who underwent immediate postmastectomy breast reconstruction at their institution between 2001 and 2006. Patient, treatment, and outcome characteristics were compared among reconstruction types: expander and implant, latissimus dorsi myocutaneous flap and implant, and autologous flap alone. Regression models were used to determine whether patient and treatment characteristics were associated with lymphedema development. This study included 1117 patients (1499 breasts), with a mean follow-up of 56 months. Axillary interventions (p < 0.001), high numbers of positive lymph nodes (p = 0.004), postoperative radiation therapy (p = 0.007), and body mass index of 25 kg/m or greater (p = 0.010) were strong predictors of increased lymphedema incidence. After excluding prophylactic mastectomy and reconstruction group changes, the authors found that the mean lymphedema incidence was 4.0 percent (of 1013 breasts). Reconstruction type had no significant effect on incidence of or time to lymphedema, and no interaction was found between axillary intervention and reconstruction type (p = 0.799). The incidence of lymphedema after immediate reconstruction was associated with high body mass index, axillary interventions, and high numbers of positive lymph nodes. The reconstructive method did not appear to affect lymphedema incidence or timing. Risk, III.